Novo Nordisk commits $2.2B to Septerna for oral obesity drug

Novo Nordisk is partnering with Septerna to develop oral pills for obesity and other cardiometabolic diseases, in a deal worth up to $2.2 billion.

Why it matters: The transaction further signals Big Pharma's interest in oral GLP-1s — which could be a cheaper and easier way to take the medicines.